The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pharmacodynamic activity demonstrated in phase I for PLX3397, a selective inhibitor of FMS and Kit.
S. P. Anthony
Research Funding - Plexxikon
I. Puzanov
Consultant or Advisory Role - Plexxikon (U)
P. S. Lin
Employment or Leadership Position - Plexxikon
Stock Ownership - Plexxikon
K. B. Nolop
Employment or Leadership Position - Plexxikon
Stock Ownership - Plexxikon
B. West
Stock Ownership - Plexxikon
D. D. Von Hoff
Research Funding - Plexxikon